Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BVT2733

Known as: BVT.2733 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND High-fat diet (HFD) induces cardiac hypertrophy; however, the underlying cellular and molecular mechanisms are yet… Expand
2013
2013
Pharmacologic glucocorticoids (GCs) inhibit osteoblast function and induce osteoporosis. 11β-hydroxysteroid dehydrogenase type 1… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2013
Review
2013
OBJECTIVE Metabolic syndrome (MetS) and Cushing's syndrome share common features. It has been proposed that increased… Expand
2012
2012
Background Inhibition of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is being pursued as a new therapeutic approach for… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
Current pharmacological treatments for obesity and metabolic syndrome have various limitations. Recently, adipose tissue 11… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2008
2008
BackgroundA substantial body of evidence indicates that reduced plasma adiponectin levels may be key in the development of… Expand
  • table 1
2008
2008
OBJECTIVE To investigate the mechanism of BVT.2733 on insulin resistance, by using diet-induced obese (DIO) mice model. METHODS… Expand
2006
2006
The NADPH-dependent enzyme type 1 11beta-hydroxysteroid dehydrogenase (11beta-HSD1) activates in a tissue-specific manner… Expand
Highly Cited
2006
Highly Cited
2006
Aims/hypothesisThe 11β-hydroxysteroid dehydrogenase type-1 inhibitor BVT.2733 lowers blood glucose and insulin in mutant mouse… Expand
  • figure 1
  • figure 2
2006
2006
AIMS/HYPOTHESIS The 11beta-hydroxysteroid dehydrogenase type-1 inhibitor BVT.2733 lowers blood glucose and insulin in mutant… Expand